A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

Authors: Bart Keymeulen, André van Maurik, Dave Inman, João Oliveira, Rene McLaughlin, Rachel M. Gittelman, Bart O. Roep, Pieter Gillard, Robert Hilbrands, Frans Gorus, Chantal Mathieu, Ursule Van de Velde, Nicolas Wisniacki, Antonella Napolitano

Published: 2020-11-04

DOI: 10.1007/s00125-020-05317-y

Source: Full article

A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

Abstract